As­traZeneca takes a chance on the STING path­way with F-star

Af­ter a slew of Big Phar­ma com­pa­nies and biotechs walked away from the STING path­way in the last few years, As­traZeneca is ap­proach­ing the field with a new bet on the drug class’ next gen­er­a­tion.

The British drug­mak­er is team­ing up with F-star Ther­a­peu­tics on a slate of pre­clin­i­cal STING in­hibitor com­pounds, the com­pa­nies an­nounced Thurs­day morn­ing. It’s a mod­est sum as these things go, with $12 mil­lion up­front and over $300 mil­lion in mile­stones, plus sin­gle-dig­it roy­al­ties.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN